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The IL-2/JAK3/STAT-5 signaling pathway is involved on the initiation and maintenance of
the transcription factor Foxp3 in regulatory T cells (Treg) and has been associated with
demethylation of the intronic Conserved Non Coding Sequence-2 (CNS2). However, the
role of the JAK/STAT pathway in controlling Foxp3 in the short term has been poorly investi-
gated. Using two different JAK/STAT pharmacological inhibitors, we observed a detectable
loss of Foxp3 after 10 min. of treatment that affected 70% of the cells after one hour. Using
cycloheximide, a general inhibitor of mRNA translation, we determined that Foxp3, but not
CD25, has a high turnover in IL-2 stimulated Treg. This reduction was correlated with a
rapid reduction of Foxp3mRNA. This loss of Foxp3 was associated with a loss in STAT-5
binding to the CNS2, which however remains demethylated. Consequently, Foxp3 expres-
sion returns to normal level upon restoration of basal JAK/STAT signaling in vivo. Reduced
expression of several genes defining Treg identity was also observed upon treatment.
Thus, our results demonstrate that Foxp3 has a rapid turn over in Treg partly controlled at
the transcriptional level by the JAK/STAT pathway.
Introduction
CD4+CD25+Foxp3+ regulatory T cells (Treg) are essential actors of the immune system [1].
Expression of the transcription factor Foxp3 is a prerequisite for their suppressive activity,
since patients carrying mutations altering the expression or function of Foxp3 may develop
IPEX (Immunodysregulation polyendocrinopathy enteropathy X-linked syndrome, a severe
autoimmune disease [2]. Also, Scurfymice, presenting a mutation in the foxp3 gene develop an
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IPEX-like disease [3,4]. Because Foxp3 is essential for function, proliferative potential and met-
abolic fitness of Treg, it is essential to gather more information on its regulation at the tran-
scriptional and post-transcriptional levels.
Genetically engineered mice have been instrumental in deciphering the molecular pathways
leading to Foxp3 expression. Mice deficient in various members of the IL-2/CD122/JAK3/
STAT-5 signaling pathway present a profound decrease in thymic and peripheral Treg [5–7].
These results have been integrated into a model where IL-2 would represent the main driver
for Foxp3 transcription in the thymus and the periphery [8]. IL-2 may affect Foxp3 regulation
through binding of the transcription factor STAT-5 to the foxp3 promoter and to the Treg-
Specific Demethylated Region (TSDR) [6,9,10] an enhancer of the Foxp3 gene that is specifi-
cally demethylated in Treg [11]. This TSDR region (also known as Conserved Noncoding
Sequence-2 (CNS2) [12]) is required for the maintenance of Foxp3 protein expression and sta-
bility of the Treg lineage, but not the initiation of Foxp3 mRNA transcription [12–14]. Further-
more, Foxp3+ cells can be generated in the thymus without IL-2 but failed to maintain in the
periphery [15,16], leading to the hypothesis that IL-2 might be more important for Treg sur-
vival in the periphery than for initiating Foxp3 expression in the thymus. Adding to this com-
plexity is the emerging view that Treg is a plastic lineage, able to convert to Teff in certain
conditions. For instance, Treg injected in lymphopenic mice converts to Foxp3- cells few weeks
after and IL-2 is able to prevent this conversion [17]. Since then, numerous examples of Treg
conversion to effector cells in inflamed tissues have been shown [1]. This conversion may
depend on limited IL-2 availability in the inflamed tissues [18,19]. Indeed, the role of an opti-
mal IL-2 signal to preserve CNS2 'activity' via recruitment of STAT-5 in dividing Treg has been
clearly demonstrated [13,14]. Also, the role of IL-2 in preventing Treg conversion in vivo has
been shown [20]. However, the effect of CNS2 deletion on Foxp3 stability was reported weeks
after in vivo transfer of modified cells and days after their in vitro activation although fine tun-
ing of the immune response would require a much more rapid adaptation to the inflammatory
milieu. Thus, the impact of IL-2 signaling on short-term regulation of Foxp3 and how it relates
to the status of CNS2 methylation in primary Treg is unknown.
Here, we used pharmacological inhibitors to block the JAK/STAT pathway in highly puri-
fied Treg from normal mice activated by IL-2 ex vivo. This strategy allows to determine the
impact of the JAK/STAT pathway on Foxp3 expression and CNS methylation on a short time
scale and in a controlled manner using cells from normal mice. Our results reveal a surprisingly
high turnover of Foxp3, regulated at the mRNA level and identify a new subset of Treg with
low expression of Foxp3 but with a demethylated CNS2, that may represent precursors of
'exTreg'.
Results
Blockade of JAK3/STAT-5 signaling pathway leads to a rapid down
modulation of Foxp3 in Treg
To determine the physiological role of the JAK3/STAT-5 signaling pathway in established
Treg, we performed in vitro experiments in which we blocked IL-2-induced phosphorylation
of STAT-5 in purified Treg with specific JAK3 inhibitors. We performed our study with two
inhibitors of the JAK3/STAT-5 signaling pathway, ZM39923 (ZM) or Tyrphostin/AG490
(AG). ZM has been described as the most specific JAK3 inhibitor whereas AG targets JAK2
and JAK3 [21]. As we previously reported [22], IL-2 induced preferential phosphorylation of
STAT-5 in Foxp3+ cells compared to Foxp3-CD4+ T cells in enriched Treg (Fig 1a). As
expected, ZM and AG inhibitors completely prevented pSTAT5 induction by IL-2 (Fig 1b). We
noticed that the proportion of Foxp3+ cells also decreased following one-hour treatment,
JAK/STAT Signaling and Foxp3 Expression
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Specific Demethylated Region; CNS2, Conserved
Non Coding Sequence 2; CHX, cycloheximide; ZM,
ZM-39923; AG, AG-490 (Tyrphostin).
Fig 1. Blockade of JAK/STAT signaling pathway leads to downmodulation of Foxp3 in Treg. (a)
CD25-enriched T cells were cultured for one hour in complete medium alone (Med.), with IL-2 (IL-2), or IL-2
supplemented with ZM-39923 (IL-2+ZM) or AG-490 (IL-2+AG). Profiles shown are gated in CD4+ cells and
are representative of 4 independent experiments. (b) Frequencies of pSTAT5+ cells among CD4+ cells
cultured for one hour with IL-2 alone (IL-2) or in presence of IL-2 and the indicated JAK inhibitors (ZM, AG).
Results are compiled from 4 independent experiments. (c) In vitro expanded CD4+GFP+ Treg were treated
with IL-2 and with either 100ug/mL of AG490 (IL-2+AG) or vehicle control (absolute ethanol; EtOH) for 2 hrs
(IL-2). Proteins were extracted in lysis buffer and blotted followed by anti-Foxp3 and anti-actin staining.
Intensity values were normalized to the actin band in each blot. The specificity of the Foxp3 staining is
attested by the absence of the Foxp3 band in extracts from splenocytes of a scurfy (genetically deficient for
Foxp3) mouse. (d) Human CD4+CD25+ cells were enriched from PBMC of healthy donors by magnetic
sorting and treated with IL-2 (600 IU/mL) with or without ZM (50 μM) for 1h. MFI of CD25 and FOXP3 in
human CD4+CD3+ cells after treatment with IL-2 alone (IL-2) or IL-2 in presence of ZM (IL-2+ZM). The MFI of
Foxp3 and CD25 shown were normalized by the MFI of control cultures. These data are compiled from 3
independent experiments. Statistical significance was tested using Student t-test (***p<0.001, **p<0.01,
*p<0.05).
doi:10.1371/journal.pone.0153682.g001
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apparently due to the down modulation of Foxp3 expression (Fig 1a). Indeed, we observed that
the Foxp3 protein was reduced 4-fold upon treatment of highly pure Treg sorted from
Foxp3-GFP reporter mice [23] compared to ethanol vehicle control (Fig 1c), suggesting that
JAK inhibitors led to a rapid loss of Foxp3 in Treg. Importantly, reduction in Foxp3 expression
upon JAK3 inhibition was also observed in purified human CD25+ cells (Fig 1d), showing that
the effect was not restricted to murine Treg. Because we observed a similar loss of Foxp3 using
murine and human Treg with both inhibitors, AG and ZM were used indifferently for the rest
of the work.
Reduced Foxp3 by JAK inhibitors is independent of cell death
One possibility to explain reduced Foxp3 in Treg would be that Foxp3+ cells preferentially died
upon treatment. In order to investigate this hypothesis, we treated sorted Foxp3+ cells with
JAK inhibitors and used a cell viability dye compatible with Foxp3 staining. Importantly, loss
of Foxp3 expression upon ZM or AG treatments occurred within live cells (Fig 2a). In addition,
decreased Foxp3 expression upon treatment with ZM did not correlate with alteration of the
anti-apoptotic factor Bcl-2 (Fig 2b), in contrast to dead cells that invariably lost Bcl-2 expres-
sion (not depicted). Thus, after exclusion of dead cells from the analysis, we observed a 60 to
70% decrease of the Foxp3 Median of Fluorescence Intensity (MFI) compared to untreated
controls in live CD4+ cells after one hour of treatment. Compared to Foxp3, CD25 expression
was less affected by the treatments (Fig 2c). Thus, loss of Foxp3 expression upon JAK3 block-
ade was independent of cell death after one hour of treatment.
To investigate the regulation of Foxp3 by the JAK/STAT pathway on a shorter time scale,
we monitored the reduction of Foxp3 expression with the AG inhibitor over a period of one
hour at 5 different time points. We observed a reduction in the MFI of Foxp3 in freshly isolated
Treg as early as 10 min of treatment, which became more pronounced overtime. In contrast,
CD25 was only marginally affected by the treatment over this time period (Fig 2d). The same
profiles were observed if the treatment was applied to CD3/CD28-activated Treg (Fig 2e),
showing that the TCR and/or co-stimulatory signaling were unable to prevent the rapid reduc-
tion of Foxp3 upon JAK/STAT signaling inhibition. Of note is that a similar reduction in
Foxp3 was observed in TGF-ß-induced Treg in vitro and that addition of TGF-β did not pre-
vent the loss of Foxp3 in Foxp3-GFP+ Treg (S1 Fig). These results show that neither TCR nor
TGF-ß signaling were able to prevent the action of JAK/STAT inhibitors.
Rapid turn over of Foxp3 protein and mRNA in Treg
Decrease in Foxp3 at the protein level could be due to reduced input, i.e reduced mRNA tran-
scription, and/or increased output, i.e increased degradation of the protein. To investigate
these possibilities, we tried to prevent loss of Foxp3 induced by the AG-490 JAK inhibitor with
two different proteasome inhibitors. However, MG-132 or Epoxomycine had only a moderate
effect at preventing Foxp3 reduction upon AG treatment (Fig 3a), indicating that most of the
reduction of Foxp3 by AG was not due to increased proteasomal degradation. Stability of
Foxp3 has been linked to the activity of the deubiquitinase USP7, protecting Foxp3 from the
proteasome [24]. We thus explored whether JAK/STAT inhibition would also impact expres-
sion of USP7. A quantitative RT-PCR analysis of purified Treg 45 min after treatment with AG
revealed a significant loss of USP7, to the same extent than Foxp3 (Fig 3b). Interestingly, the
STUB1 ubiquitinase mRNA, described as an inducer of Foxp3 proteasomal degradation [25],
was not changed after treatment. Overall, these results indicate that proteasomal degradation
of Foxp3 upon JAK/STAT inhibition might operate through diminished activity of the Foxp3-
protecting USP7 deubiquitinase but that was not responsible for most of the changes.
JAK/STAT Signaling and Foxp3 Expression
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We thus performed quantitative RT-PCR to assess whether loss of Foxp3 would be better
explained by reduced transcription of Foxp3 mRNA. We observed a very similar reduction
kinetics for Foxp3 mRNA than for the protein by TaqMan qPCR. Foxp3 mRNA was reduced
by half in the first 20 min after treatment compared to vehicle-treated cells (Fig 3c). Thus, JAK/
STAT signaling inhibition rapidly impacted Foxp3 mRNA transcription and /or stability,
which in turns translated to reduced Foxp3 protein levels. To determine whether this rapid loss
of the protein was reproduced in the absence of mRNA translation, we treated Foxp3+GFP+
Treg with a subtoxic dose of cycloheximide (CHX), an mRNA translation inhibitor. We
Fig 2. Reduced Foxp3 by JAK/STAT inhibitors is independent of cell death. (a) CD4+GFP+ T cells
sorted from Foxp3-GFP transgenic mice were stimulated with anti-CD3/CD28 beads for 8 days and treated
with vehicle and IL-2 (IL-2), or IL-2 supplemented with ZM (IL-2+ZM) or AG (IL-2+AG) JAK inhibitors for two
hours. Cells were then stained with a dye allowing exclusion of dead cells by flow cytometry compatible with
Foxp3 intracellular staining. Profiles are representative of 6 and 7 independent experiments for AG and ZM
inhibitors, respectively. (b) Foxp3 and Bcl-2 expression in gated CD4+CD25+ cells from expanded
CD4+GFP+ cells after 2 hour treatment with vehicle control and IL-2 (IL-2) or ZM in presence of IL-2 (IL-2
+ZM). Similar results were observed in 3 independent experiments. (c)Median fluorescence intensity (MFI)
of CD25 and Foxp3 in dead cell–excluded subset, represented as percentages of the MFI relative to Foxp3
staining in vehicle control condition (control) after two hours treatment with the indicated inhibitors. The
results are compiled from 6 (AG) and 7 (ZM) independent experiments. (d) Freshly isolated or (e) anti-CD3/
CD28 activated CD4+GFP+ cells from Foxp3-eGFP reporter mice were treated for the indicated times with
either ZM or AG inhibitors. MFI of CD25 and Foxp3 are relative to the MFI of vehicle control conditions. These
data are compiled from 3 independent experiments. Statistical significance was tested using Student t-test
(***p<0.001, **p<0.01, *p<0.05).
doi:10.1371/journal.pone.0153682.g002
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observed a sharp decrease in Foxp3 expression as early as 10 min of treatment and an almost
complete disappearance of the staining in 30 minutes with that dose. The decrease in the MFI
of CD25 was much slower and less pronounced than Foxp3 (Fig 3d). Thus, this experiment
confirms that the Foxp3 protein has a rapid turnover in Treg, that depends of continuous
mRNA translation.
Reduced Foxp3 in Treg by JAK inhibitors is not due to remethylation of
the CNS2 and is reversible
Since STAT-5 is a major player of Foxp3 transcription by binding to multiple regulatory
regions in the Foxp3 gene, release of STAT-5 from the Foxp3 gene was one possible explana-
tion for reduced mRNA transcription. Because the CNS2 is essential for Foxp3 stability, we
determined whether STAT-5 was released from a putative binding site within the CNS2
(STAT1-binding site region 418–426 according to Floess et al. [11] or the GAS (IFN-Gamma
Activated Sites) motif 4384–4393 according to Kim and Leonard [26]. We could demonstrate
that STAT-5 was indeed bound to the CNS2 at this location in vehicle-treated Treg cells. This
specific binding was lost following JAK/STAT signaling inhibition (Fig 4a), showing that
STAT-5 was released from the CNS2.
Fig 3. Rapid turn over of the Foxp3 protein andmRNA in Treg. (a)MFI of Foxp3 on GFP+ Treg treated
with proteasome inhibitors MG-132 or Epoxomycine (Epox) in presence of IL-2 and AG for 2 hrs. Cells were
pretreated during 2 hrs with the proteasome inhibitors before adding AG. (b) Foxp3, USP7 and STUB1
mRNA were quantified using the TaqMan RT-PCR assay normalized to vehicle control conditions 45 minutes
after AG-treatment in expanded CD4+GFP+ cells by the 2-ΔΔCt method (see method section). This result
originate from a single experiment performed in triplicates. (c) Foxp3 mRNAwas assessed by quantitative
RT-PCR normalized to vehicle control conditions at the indicated times after AG-treatment in expanded
CD4+GFP+ cells by the 2-ΔΔCt method (see method section). The experiment was repeated 3 times. Each dot
represent the mean ± SDEV of results obtained in 3 independent experiments. Two outliers were removed
from the calculation (d)MFI of Foxp3 and CD25 in cycloheximide-treated sorted activated CD4+GFP+ cells
relative to the vehicle control at the indicated times. Results are compiled from 3 independent experiments.
doi:10.1371/journal.pone.0153682.g003
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Since the CNS2 is fully demethylated ex vivo in isolated Treg and methylated in conven-
tional T cells [11], we sought to determine whether reduced Foxp3 expression was associated
with remethylation of the CNS2. As expected, we observed a fully demethylated CNS2 in
freshly purified CD4+GFP+ cells and a fully methylated TSDR in CD4+GFP- cells (Fig 4b). The
methylation status of the CNS2 was not significantly affected 4 or 6 hours after treatment with
ZM relative to untreated cells (Fig 4b). At this time, Foxp3 expression was still low in viable
Treg (not shown). Thus, the loss of Foxp3 did not originate from increased methylation of the
CNS2, suggesting that the rapid loss of Foxp3 described above was also unlikely to be due to
remethylation of the CNS2.
The lack of CNS2 remethylation upon JAK/STAT inhibition suggests that the loss of Foxp3
could be reversible upon restoration of this signaling pathway. To determine whether loss of
Foxp3 was reversible, AG-treated Treg cells having lost 70% of Foxp3 were transferred into
normal congenic mice to restore the basal JAK/STAT signaling that Treg may encounter in
vivo. A sharp increase in Foxp3 levels was observed 6 hours after transfer, and the MFI of
Foxp3 was indistinguishable from untreated cells overnight after transfer in vivo (Fig 4c). Thus,
the loss of Foxp3 expression upon transient inhibition of IL-2 signaling was reversible upon
restoration of basal JAK/STAT signaling in vivo.
Fig 4. Loss of Foxp3 is not due to remethylation of the CNS2 and is reversible. (a) STAT5 binding on a
putative binding site in the TSDR enhancer of the foxp3 gene was assessed by chromatin
immunoprecipitation with control IgG or anti-STAT-5 antibodies. Quantification of binding was performed as
described in Methods section. These data are from one representative experiment out of two. (b) Methylation
status of the Foxp3 TSDR was determined by bisulphite sequencing. Expanded CD4+GFP+ T cells were
treated with IL-2 and ZM (IL-2+ZM) for 4 (4 hrs) or 6 (6 hrs) hours. Freshly purified CD4+GFP+ (GFP+),
CD4+GFP- (GFP-), or untreated expanded cells (IL-2) were used as controls. These data are representative
of two independent experiments. Each line indicate the position in the Foxp3 locus (CpG), according to
Floess et al. [11]. A shaded scale of grey illustrates the frequency of each methylated CpG. (C) For in vivo
analysis, expanded CD4+GFP+ cells treated or not with AG for two hours were injected into congenic C57BL/
6 mice. Animals were euthanized at the indicated times after transfer. The MFI of Foxp3 was normalized to
vehicle-treated control cells.
doi:10.1371/journal.pone.0153682.g004
JAK/STAT Signaling and Foxp3 Expression
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Global impact of JAK/STAT signaling inhibition in Treg at the molecular
level
In order to determine whether inhibiting JAK/STAT signaling pathway in Treg might impact
other genes than Foxp3 in the short term, we performed a comparative analysis of the tran-
scriptome in ZM-treated or untreated CD4+GFP+ Treg. Using a 1.5-differential fold-change
expression cut-off, 110 genes were down-regulated and 51 genes were up-regulated after a 2
hour treatment, including some genes involved in canonical pathways independent or associ-
ated with JAK/STAT signaling (Pias-1, Ets-1) (Fig 5a). Among the 110 down-regulated genes,
several have been associated with Treg function and/or regulation of Foxp3 expression, like
CD73 [27], furin [28] pias-1 [29], Eos (ikzf4) [30] or Ets-1 [10]. We confirmed by qPCR that
Eos mRNA levels were strongly reduced in this experiment, and observed a tendency for the
loss of Ets-1 mRNA as well (Fig 5b). The treatment with the ZM inhibitor also altered the
expression of a few genes from the Treg signature and of many target genes for Foxp3 (S2 Fig).
Of note is that despite the reported affinity for JAK3, genes from signaling pathways other than
JAK/STAT were affected by the ZM inhibitor (S2 Fig). Among those, the MAPK pathway
might have played a specific role since ERK signaling has been associated with lower expression
of Foxp3 [31]. Thus, our results reveal that several genes involved in Treg identity were also
maintained by the JAK/STAT pathway in the short term.
Discussion
To our knowledge, few studies have investigated the impact of JAK/STAT inhibitors on estab-
lished Treg in vitro [32,33] and in vivo [34] and never on the very short time scale that we
report here. Moreover, dead cells were not excluded from most of these analysis and no molec-
ular data on mRNA levels or methylation of the CNS2 were provided. Thus, our results signifi-
cantly expand our knowledge on the regulation of Foxp3, a crucial transcription factor for
maintenance of immune homeostasis [35,36], and provide clues on how an established Treg
may convert to an effector T cells.
Our analysis of the early events after inhibition of the JAK/STAT signaling pathway reveals
an unexpected rapid turn over of Foxp3, perhaps the most striking result of our study. We
Fig 5. Molecular impact of JAK/STAT signaling inhibition in Treg. (A) Scatter plot comparison of average
expression values in ZM-treated cells (ZM) versus vehicle-treated cells (DMSO) for all the 45,282 probes in
expanded CD4+GFP+ T cells from Foxp3-eGFP mice treated for 2h in presence of IL-2. (B)mRNA
quantification by Taqman RT-PCR on Ets-1 and Eos (Ikzf4) in 2hrs ZM-treated cells relative to control values
in untreated cells.
doi:10.1371/journal.pone.0153682.g005
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confirmed this rapid turn over using CHX, a wide inhibitor of mRNA translation. Previous
studies assessing the stability of Foxp3 expression upon CHX treatment gave values for Foxp3
‘half-life’ ranging from 20 min to several hours depending on the model [37,38]. Based on the
slopes that we obtain with the CHX inhibitor, we would estimate a much shorter half-life for
Foxp3 of 9.8 min in murine primary Treg. The similarity in Foxp3 reduction kinetics between
JAK3 inhibitors and CHX suggests that most of the turn-over of Foxp3 would depend on JAK3
activity. Furthermore, our qPCR data reveals that the loss of Foxp3 mRNA mirrors the loss of
the Foxp3 protein. Altogether, our results suggest a constant input of Foxp3 mRNA at steady
state in Treg, leading to the renewal of 50% of new Foxp3 proteins every 10 min or so. In the
absence (or strong reduction) of IL-2 signaling, reduced input of mRNA would rapidly trans-
late into the loss of the protein. Our results are in line with the proposition that cellular protein
levels are mostly constrained at the mRNA translation level. Moreover, they also concurs with
molecular studies showing that transcription factors are in the group of molecules with the
shortest half-lives [39]. Further studies are needed to decipher the exact mechanisms behind
the control of Foxp3 mRNA by the JAK/STAT signaling pathway, but microRNAmight be
involved since it has been shown that miR31 directly interact with Foxp3 mRNA to repress
expression of the protein [40]. Interestingly, at least one miR (miR182) has been described to
be under the control of IL-2 in T cells [41].
Recently, it was demonstrated that the proteasome plays a central role in Foxp3 stability
[24,25]. Our results failed to show any significant prevention on the loss of Foxp3 with protea-
some inhibitors. However, the USP7 gene, proposed as an important stabilizer of Foxp3 [24],
was reduced to a similar extent than Foxp3 following JAK/STAT inhibition, suggesting that a
reduction in USP7 activity might have been responsible for directing Foxp3 to an alternative
pathway of ubiquitin-dependent degradation. These contrasting results might in part be
explained by toxicity of proteasome inhibitors relative to JAK/STAT inhibitors. The exact
mechanism by which the Foxp3 protein is lost upon JAK/STAT inhibition remains to be
determined.
Supporting the hypothesis that IL-2 signaling is mainly involved in the control of Foxp3
mRNA transcription, we show here that STAT-5 is bound to the GAS-region of the CNS2
upon IL-2 signaling, and released upon inhibition of this signaling. Thus, it is tempting to spec-
ulate that a continuous IL-2 signal would be needed for STAT-5 binding to the Foxp3 and sub-
sequent Foxp3 mRNA transcription. This hypothesis is supported by results showing that the
CNS2 needs to be 'activated' by IL-2 to maintain Foxp3 expression [13]. However, we report
here that the loss of Foxp3 expression was not accompanied by remethylation of the CNS2,
showing that Foxp3 expression and methylation of CNS2 are not always associated. This result
confirms previous studies performed with murine Treg in vivo [20] and with human Treg ex
vivo [42]. Although these studies showed that IL-2 signaling pathway was defective in human
'exTreg' [42] and that IL-2/IL-2R complexes were able to prevent Treg conversion in vivo [20],
our data are the first, to our knowledge, to show that the loss of Foxp3 upon JAK/STAT inhibi-
tion is reversible if physiological levels of IL-2 are provided. This strongly suggest that IL-2 is
permanently controlling Foxp3 transcription in vivo, explaining why pSTAT5 is associated
with Foxp3 expression in freshly isolated Treg [22] and in close vicinity with IL-2-producing
cells in vivo [43].
It has also been reported that the TCR signal is important to maintain Foxp3 due to an ade-
quate chromatin 3D architecture [14]. We found here that the extent of FoxP3 reduction upon
JAK/STAT inhibition was similar in TCR-stimulated cells or not. This suggest that the JAK/
STAT pathway might be dominant over the TCR pathway to maintain Foxp3 in Treg. In acti-
vated or resting Treg, 30 to 40% of Treg 'resisted' the treatment, establishing the proportion of
'plastic' Treg to 60 to 70% of all Treg, a relatively similar figure than the one determined on
JAK/STAT Signaling and Foxp3 Expression
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TCR-activated Treg [13] and slightly higher than the one proposed in vivo during EAE [20]. It
has been suggested that TGF-ß might play an important role on methylation of CNS2 through
STAT-5 [44]. Whether TGF-ß plays a role in remethylation of the CNS2 in the absence of IL-2
signaling remains to be investigated.
In summary, our results significantly expand our knowledge on the regulation of Foxp3 at
the cellular and molecular level. We show that Foxp3 has a short half life controlled by the
JAK/STAT signaling pathway mostly at the level of mRNA transcription and/or stability. They
also establish that loss of Foxp3 can be observed in a context of a demethylated CNS2. 'ExTreg',
the existence of which has been disputed in the past [45], have now been described in numer-
ous studies and have their CNS2 remethylated in some [13] but not all [20,42] studies. Thus,
we would like to suggest that the population of Foxp3loCD25+ cells with a demethylated CNS2
that are generated in vitro very rapidly after cessation of the JAK/STAT signaling pathway
might represent the precursors of 'exTreg'. These precursors might be rapidly generated in vivo
in conditions of limited IL-2 availability and/or prolonged inflammatory conditions. A com-
plete understanding on the extra and intracellular signals leading to full dedifferentiation of
Treg will be important for a better comprehension of immune homeostasis.
Materials and Methods
Mice
C57BL/6J Ly5.2 (CD45.2+ CD90.2+) mice were purchased from Janvier Labs (Le Genest Saint
Isle, France). Foxp3-eGFP C57BL/6 Ly5.2 mice were obtained courtesy of Dr. Bernard Malissen
(Centre d'Immunologie de Marseille-Luminy, France). For some experiments, Foxp3-eGFP mice
were crossed with congenic CD90.1+ mice. All animals were kept under specific pathogen-free
conditions and manipulated according to European council directive 86/609/EEC. Briefly, mice
were given 3% fat food and acidified water ad libitum and were maintained under a 14-hour light
10-hour dark cycle. Animals were euthanized by cervical dislocation after isoflurane anesthesia.
The study was approved by the Ethical Committee of Région Ile-de-France (ref p3/2008/039).
Cell purification and sorting
Human cells were obtained from leuko-apheresis samples freshly collected from healthy donors
from the EFS (Etablissement Français du Sang), after informed consent and under an institu-
tional agreement with the EFS. Peripheral blood mononuclear cells (PBMC) were separated on
Ficoll-Hypaque gradient (PAA laboratories, Pasching, Austria). CD25+ cells were enriched from
PBMC using CD25 microbeads II, LS columns and a MidiMACS separator (Miltenyi).
Murine CD25-enrichment was performed on pooled spleens and peripheral lymph nodes
cells prepared by mechanical dissociation in PBS 1X supplemented with 3% FCS. Cells were
sequentially incubated for 20 minutes at 4°C with saturating amounts of biotin-labeled anti-
CD25 mAb (clone 7D4; BD) and then, anti-biotin microbeads (Miltenyi), followed by two
rounds of magnetic cell separation in LS columns. Alternatively, cell sorting was performed
using the auto-MACS (Miltenyi). A purity of 50% to 60% of CD4+CD25+ cells, containing 70%
to 80% of Foxp3+ cells, was regularly observed. Cell sorting from Foxp3-eGFP mice was per-
formed with one LS column, followed by staining with anti-CD4 mAb and sorted with a FAC-
SAria (BD) on the basis of CD4 and GFP expression, ensuring purity greater than 96%.
In vitro treatments
In most experiments, CD4+GFP+ purified T cells were cultivated for four to twenty-five days in
RPMI 1640 (Life Technologies, Paris, France) supplemented with 10% FCS, 2 mM glutamine,
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100 U/ml penicillin, 100 mg/ml streptomycin, 50 μM β-Mercaptoethanol and 10 mMHEPES,
with Dynabeads Mouse T-activator CD3/CD28 (Life Technologies, 2 beads for 1 T cell) and
10 ng/ml mIL-2 (Peprotech, Paris, France), at a concentration of 106 cells/ml, and incubated in
a 37°C, 5%CO2 incubator. Fresh mIL-2 was added every 2–3 days. Cycloheximide (CHX),
ZM39923 (ZM) and Tyrphostin/AG490 (AG) (Sigma Aldrich) were diluted in 100% DMSO
(CHX, ZM) or absolute ethanol (AG) and were used at final concentrations of 30 μM for ZM,
50–200μg/ml for AG and 10 μg/ml for CHX. The proteasome inhibitors Epoxomycine and
MG-132 (Sigma) were diluted in 100% DMSO and were used at a final concentration of 5μM.
For experiments with expanded CD4+GFP+ T cells, inhibitors were added directly in culture
medium or 24h after removal of CD3/CD28 Dynabeads. Treatment was performed on 0.1x105
to 106 cells per well at a concentration of 106 cells/ml. For freshly purified or enriched T cells,
cells were grown in complete RPMI 1640 medium, in presence of mIL-2 at 10 ng/ml. For
human studies, cells were cultivated in RPMI 1640 medium supplemented with 10% human
serum, 2% penicillin/streptomycin and 1% L-Glutamine, and with recombinant human IL-2
(600 IU/ml).
To generate TGF-ß-induced Treg, CD4+CD25-CD44lowGFP- T cells were purified from
spleen and peripheral lymph nodes of Foxp3-GFP mice by flow cytometry cell sorting. Cells
were grown for 4 days culture in a 37°C, 5% CO2 incubator with plate-bound anti-CD3 (clone
145-2C11, BD) (1 μg/ml) and anti-CD28 (1 μg/ml), in combination with human TGF-β
(Peprotech) (10 ng/ml) and mIL-2 (Peprotech) (10 ng/ml). Anti-CD122 mAb (TMβ1) was pre-
pared by Agro-Bio (La Ferté Saint-Aubin, France) from ascites or obtained from BioXCell
(West Lebanon, NH, USA) and was used at a final concentration of 10 μg/ml.
Flow cytometry and monoclonal antibodies
The following monoclonal antibodies were used for phenotypic analysis: for mice studies:
Alexa Fluor 700- or phycoerithrin (PE)-labeled anti-CD4 (clone RM4-5, BD), peridinin-
chlorophyll-protein (PercP)-labeled anti-CD8 (clone 53–6.7, BD), PE-Cyanin7 (PECy7)-con-
jugated, allophycocyanin (APC)- or PE-labeled anti-CD25 (clone PC61, respectively from
eBioscience and BD), Pacific blue- or eFluor 450-labeled anti-Foxp3 (clone FJK16s,
eBioscience), PE-labeled anti-Foxp3 (clone FJK16s, BD), Alexa Fluor 647-labeled anti-Foxp3
(clone MF23, BD), PercP-labeled CD90.1 (OX-7, BD) and PE-labeled anti-Bcl-2 (clone 3F11,
BD). For human studies: PE-labeled anti-CD25 (clone M-A251, BD or 4E3, Miltenyi Biotec,
Paris, France), PercP-labeled anti-CD4 (clone SK3, BD), PE-Cyanin7-labeled anti-CD3 (clone
UCHT1, Biolegend, San Diego, CA, USA), Alexa Fluor 488- or APC-labeled anti-FOXP3
(clone 236A/E7, eBioscience) and Alexa Fluor 700-labeled anti-CD8 (clone HIT8a, Biolegend).
Alexa fluor 647-labeled anti-pSTAT5 (Y694, BD) was used in both mice and human studies.
For cell surface staining, 105 to 106 cells were labeled with 50–100 μl of a mix of mAbs at
proper concentrations in PBS containing 3% FCS for 20–30 minutes at 6–8°C in the dark.
Staining with the Fixable Viability Dye eFluor 780 (eBioscience, Paris, France) or with the Live
Dead viability assay Green dead cell stain kit (Life Technologies, Saint Aubin, France) was per-
formed before cell surface staining, according to the manufacturer’s instructions. Intracellular
staining using Foxp3 mAb was performed according to the manufacturer’s instructions
(eBioscience). Detection of pSTAT5 was already described in details [22]. Briefly, cell suspen-
sions were fixed with 10 volumes of PBS 1X 1.5% formaldehyde for 10 minutes at room tem-
perature. Cells were then washed in PBS 1X 0.2% BSA, and permeabilized with 100% methanol
for 10 minutes on ice. After extensive washing, cells were incubated for 45 minutes in the dark
at 6–8°C. Fluorescent signals were collected on a FACS LSR II (Becton Dickinson (BD), San
Diego, CA, USA). Proper compensation using Fluorescence Minus One (FMO) controls were
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established with the FlowJo software (TreeStar, Ashland, OR). To accommodate for variations
in the MFI of Foxp3 and CD25 among different experiments, results are presented as percent-
ages of controls, representing an index between the MFI of the molecule of interest in presence
of the inhibitors divided by the MFI of the same molecule in presence of the vehicle control. In
some experiments, the delta between the MFI of Foxp3+ and Foxp3- cells in the same sample
was also taken into account for the calculations.
Foxp3, USP7 and STUB1 RT-PCR assay
Reverse transcription was performed on 106 AG- or EtOH-treated CD4+GFP+ expanded Treg
cells from Foxp3-eGFP reporter mice. RNA was extracted from cell pellets using the RNAeasy
extraction kit (Qiagen, Hilden, Germany). Then, reverse transcription was performed with the
kit Superscript III (Life Technologies). Finally, cDNA was amplified by real-time PCR with the
Taqman Gene expression assay (Applied Biosystems-Life Technologies) following the manu-
facturer’s instruction. Real-time PCR was performed with a ABI PRISM17700 Sequence
Detector (Applied Biosystems, Carlsbad, CA, USA). Quantitation of mRNA expression of
Foxp3 in AG-treated vs EtOH-treated cultures was determined using the 2-ΔΔCT hypothesis









Proteins were extracted from cell pellets in lysis buffer (RIPA, Thermo Scientific) containing
protease inhibitor cocktail (Pierce) and phosphatase inhibitor cocktail (Sigma). Proteins were
separated in precast NuPAGE Novex 4–12% Bis Tris Protein Gels in NuPage MOPS SDS run-
ning buffer and transferred to PVDF membranes with iBlot system (all from Life Technolo-
gies). After incubation with anti-Foxp3 (Cell Signaling) or anti-beta Actin (Abcam) overnight
at 4°C, proteins were detected using species-specific biotinylated secondary antibodies and
Qdot 625 streptavidin conjugate (Invitrogen). Signals were quantified by densitometry with
ImageJ 1.45 software (NIH, Bethesda, USA).
Chromatin immunoprecipitation and methylation assay
ChIP assay was performed using the Magnify ChIP system, according to the manufacturer
instructions (Life Technologies). Briefly, cells in culture were fixed using formaldehyde-based
buffers. Chromatin was sheared by brief pulse of ultrasound on ice and anti-STAT5 (clone
ST5b-10G1, mouse anti-human STAT5b, Life Technologies) or control mouse IgG (Life Tech-
nologies) was used to pull-out the transcription factor associated to the chromatin. Fixation
was reverted and DNA was purified using magnetic beads. This DNAmaterial was subjected to
quantitative PCR using SYBR Green Master mix (Life Technologies) on a ABI PRISM1 7700
Real Time PCR System. Primers used were specific for the putative STAT5 binding site in the
TSDR region of the murine foxp3 gene: foxp3-for (5’!3’): AGAACTTGGGTTTTGCATGG;fox-
p3-rev (5’!3’): ACTTGGCCAGATTTTTCTGC. Relative occupancy was calculated according to
the following formula: 2 (CtNegCtrl−
Ct
Target
) x100 where CtNegCtrl and CtTarget are median
threshold cycles of PCR done in triplicates on DNA samples from the Negative Control ChIP
(using non-immune IgG) and targeted ChIP (using specific antibody) respectively.
Genomic DNA was isolated from ZM- or DMSO-treated CD4+GFP+ expanded Treg cells of
Foxp3-eGFP mice using the DNeasy tissue kit (Qiagen) following the supplier's recommenda-
tions. Bisulphite sequencing was performed as described [46].
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DNAmicroarray hybridization and analysis
RNA from 2x106 DMSO- or ZM39923-treated expanded CD4+GFP+ cells of Foxp3-eGFP mice
was generated using RNeasy Mini kit (QIAGEN) and its quality was verified in an Agilent
Bioanalyzer. Total RNA was amplified and converted to biotinylated cRNA according to the
manufacturer’s protocol (Illumina TotalPrep RNA Amplification Kit; Ambion). Two biological
duplicates were hybridized to the Sentrix BeadChips Array mouse WG-6 v2 (Illumina). Heat-
map representation of log2 expression data was generated using R and Treeview software using
the Euclidean correlation similarity measure and complete linkage algorithm. Scatter plot was
performed using a log2 representation.
Statistical analyses
Two-tailed unpaired t test with 95% confidence intervals were performed using GraphPad
Prism version 5.0 for PC (GraphPad Software, San Diego, CA). Mean values were considered
statistically different if the p value was below 0.05.
Supporting Information
S1 Fig. Reduction of Foxp3 upon JAK/STAT inhibition is not compensated by TGF-ß sig-
naling.
(PDF)
S2 Fig. JAK inhibitors affect several genes involved in Treg identity.
(PDF)
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